| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 9 May 2025 | 1 May 2025 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2025 inter alia to consider and approve Audited Standalone Financial Results of the Company For the Year and Quarter Ended 31st March 2025. The Board of Directors of the Company have approved the Audited Financial Results for the Quarter and Year ended March 31st 2025 at their meeting held on May 9, 2025. (As Per BSE Announcement Dated on: 09/05/2025) | ||
| Board Meeting | 26 Apr 2025 | 26 Apr 2025 |
| The Board of Directors appointed Mrs. Priyanka Agarwal, member of ICSI (A36112) as the Company Secretary & Compliance Officer of the Company w.e.f 26th April 2025. | ||
| Board Meeting | 21 Apr 2025 | 21 Apr 2025 |
| Resignation of Ms. Pratibha Jhawar from the post of Company Secretary & Compliance officer. | ||
| Board Meeting | 20 Mar 2025 | 21 Mar 2025 |
| Allotment of Equity Share Warrants pursuant to Preferential Issue under the provisions of Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and applicable provisions of Companies Act 2013 and the rules made thereunder, each as amended (the Preferential Issue) | ||
| Board Meeting | 8 Feb 2025 | 3 Feb 2025 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2025 inter alia to consider and approve Board Meeting to be held on 8th February 2025 inter alia to consider and approve the Un-Audited Financial Results For The Quarter Ended December 31 2024. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors has approved the unaudited Standalone Financial Results for the quarter and Nine Months ended 31st December, 2024. (As Per BSE Announcement Dated on 08/02/2025) | ||
| Board Meeting | 11 Jan 2025 | 6 Jan 2025 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/01/2025 inter alia to consider and approve Intimation of Board Meeting pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 regarding increase in the Authorised Capital and Issue of share warrants and Issue of Equity shares on preferential basis. In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015 we are herewith enclosing the Outcome of the Board Meeting held on 11.01.2025. (As Per BSE Announcement Dated on: 11/01/2025) | ||
| Board Meeting | 27 Dec 2024 | 27 Dec 2024 |
| The Board has considered and accepted the Resignation of Mr. Nooka Krishnaiah from the position of Managing Director and Director of the Company. | ||
| Board Meeting | 11 Nov 2024 | 30 Oct 2024 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve Board Meeting Intimation for the Meeting of The Board Of directors is to be held on Monday November 11 2024 For Considering The Un-Audited Financial Results For The Quarter Ended September 30 2024. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors has approved the unaudited Standalone Financial Results for the quarter and Half Year ended 30th September, 2024. Read less.. (As Per BSE Announcement Dated on: 11/11/2024) | ||
| Board Meeting | 1 Oct 2024 | 1 Oct 2024 |
| Appointment of Mr. Sadhanala Venkata Rao as Additional Director-Whole time Director. | ||
| Board Meeting | 2 Sep 2024 | 2 Sep 2024 |
| Intimation of appointment of Company Secretary and Compliance Officer | ||
| Board Meeting | 22 Aug 2024 | 16 Aug 2024 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/08/2024 inter alia to consider and approve To discuss matter related to Annual General meeting The Board of Directors has approved the Directors Report and the Notice of 32nd Annual General Meeting and other Related Matters. (As Per BSE Announcement dated on 22.08.2024) | ||
| Board Meeting | 12 Aug 2024 | 2 Aug 2024 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve The Board Meeting is scheduled to be held on August 12 2024 for considering the Un-Audited Quarterly Financial Results for the June 2024 Quarter. Submission of Unaudited Financial Results for the Quarter ended 30.06.2024 approved by the Board of Directors Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE Announcement dated on 12.08.2024) | ||
| Board Meeting | 14 May 2024 | 7 May 2024 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve This is to inform that the Meeting of the Board of Directors is scheduled to be held on Tuesday May 14 2024 to consider and approve inter-alia the Audited Standalone Financial Results of the Company for the Year and Quarter ended March 31 2024. Submission of Audited Financial Results along with Auditors Report with unmodified opinion for the quarter and financial year ended 31st March, 2024. (As Per BSE Announcement Dated on 14/05/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
